Regulatory press release

Cinclus Pharma’s Nomination Committee proposes new representative for the company’s founders to the Board

Cinclus Pharma Holding AB (publ) (”Cinclus Pharma”) announced today that the Nomination Committee proposes that co-founder Kjell Andersson be elected as a new member of the Board of Directors at an Extraordinary General Meeting. Kjell Andersson is proposed to succeed Peter Unge, who has expressed his wish to step down from his position on the company’s Board.

“Peter has shown great dedication to Cinclus Pharma since he, together with Kjell and others, founded the company in 2014. Now that we have reached the important milestone of initiating our first Phase III study, Peter has expressed a wish to hand over his responsibilities on the Board. We would like to express our deep appreciation for Peter’s commitment and valuable contributions to the company’s development and we are pleased that he will continue to support us as a member of Cinclus’ Scientific Advisory Board. With Kjell’s unique experience and expertise in the development of reflux treatments, we gain an extremely valuable addition to the Board while ensuring continuity within the company,” says Lennart Hansson, Chair of the Board of Cinclus Pharma.

The election of the new Board member will be addressed at an Extraordinary General Meeting intended to be held on 19 January 2026. A notice convening the meeting will be published separately ahead of the Extraordinary General Meeting. Peter Unge will remain a member of the Board until the Extraordinary General Meeting and will thereafter join Cinclus’ Scientific Advisory Board.

About Kjell Andersson
Kjell Andersson, born in 1957, is one of the founders of Cinclus Pharma. He is one of Sweden’s most experienced drug developers in acid-secretion inhibition and has played a key role in developing globally successful treatments for reflux disease. Kjell has a long background at AstraZeneca, where he served, among other roles, as preclinical project leader for the development of linaprazan, which forms the basis of Cinclus Pharma’s drug candidate linaprazan glurate. Further information about Kjell Andersson will be provided in the notice to the Extraordinary General Meeting.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.